RESUMEN
Guidance for managing potential dermal exposures has historically been qualitative in nature, for example, in the form of a DSEN notation. We propose a method that can provide quantitative guidance on how to establish and use surface wipe limits for skin sensitizers. The murine local lymph node assay (LLNA) is a validated test that not only identifies potential skin sensitizers but also provides an effective concentration (EC3) value. This provides quantitative dose-response information on induction of skin sensitization that permits estimates of sensitization thresholds and potency. Building upon the previously established correlation between LLNA EC3 values and human repeat insult patch testing no-effect levels, we present a quantitative method for setting surface wipe guidelines using the LLNA EC3. These limits can be used to assign compounds to occupational exposure bands and provide handling guidance for skin sensitizers of varying potency, supporting both exposure assessment and control strategies. A table is included that suggests a band of reasonable surface wipe limits (mg/100 cm2) for potentially all chemical sensitizers. When used in conjunction with a comprehensive industrial hygiene program that includes hazard communication, engineering controls, and personal protective equipment, skin exposure and consequent skin sensitization risks in the workplace can be minimized.
Asunto(s)
Dermatitis Alérgica por Contacto/etiología , Exposición Profesional/normas , Animales , Cosméticos/efectos adversos , Dermatitis Alérgica por Contacto/prevención & control , Humanos , Ensayo del Nódulo Linfático Local , Ratones , Medición de Riesgo , Piel/efectos de los fármacos , Pruebas Cutáneas/métodos , Pruebas Cutáneas/normasRESUMEN
Historically, pharmaceutical industry regulatory guidelines have assigned certain active pharmaceutical ingredients (APIs) to various categories of concern, such as "cytotoxic", "hormones", and "steroids". These categories have been used to identify APIs requiring segregation or dedication in order to prevent cross-contamination and protect the quality and safety of drug products. Since these terms were never defined by regulatory authorities, and many novel pharmacological mechanisms challenge these categories, there is a recognized need to modify the historical use of these terms. The application of a risk-based approach using a health-based limit, such as an acceptable daily exposure (ADE), is more appropriate for the development of a Quality Risk Management Program (QRMP) than the use of categories of concern. The toxicological and pharmacological characteristics of these categories are discussed to help identify and prioritize compounds requiring special attention. Controlling airborne concentrations and the contamination of product contact surfaces in accordance with values derived from quantitative risk assessments can prevent adverse effects in workers and patients, regardless of specific categorical designations to which these APIs have been assigned. The authors acknowledge the movement away from placing compounds into categories and, while not yet universal, the importance of basing QRMPs on compound-specific ADEs and risk assessments. Based on the results of a risk assessment, segregation and dedication may also be required for some compounds to prevent cross contamination during manufacture of APIs.
Asunto(s)
Contaminación de Medicamentos/prevención & control , Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Industria Farmacéutica/historia , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Historia del Siglo XXI , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/historia , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/historia , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Control de Calidad , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
Acceptable daily exposures (ADEs) are established to determine the quantity of one drug substance that can contaminate another drug product without causing harm to the patient. An important part in setting an ADE for a drug substance, after identification of the unwanted critical effect(s) of the compound (see Bercu et al., 2016, this issue), is the determination of an appropriate overall margin of safety that is need to be maintained below the dose causing a certain critical effect (i.e., the point of departure or PoD). The overall margin of safety used to protect the general patient population from critical effects is derived as the product (i.e., composite adjustment factor) of various individual factors that account for variability and uncertainty in extrapolating from the PoD to an ADE. These factors address the considerations of interindividual variability, interspecies extrapolation, LOAEL-to-NOAEL extrapolation, exposure duration adjustment, effect severity, and database completeness. The factors are considered individually, but are not necessarily independent and their interdependence should be identified, with subsequent adjustment to the composite factor, as appropriate. It is important to identify all sources of variability and uncertainty pertinent to the derivation of the ADE and ensure each is considered in the assessment, at least by one of the adjustment factors. This manuscript highlights the basis for and selection of factors that address variability and uncertainty as used in the guidance documents on setting ADEs or other related health-based limits.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Relación Dosis-Respuesta a Droga , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Modelos Biológicos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Especificidad de la Especie , Pruebas de ToxicidadRESUMEN
The purpose of this paper is to describe the use of toxicokinetic (TK) and toxicodynamic (TD) data in setting acceptable daily exposure (ADE) values and occupational exposure limits (OELs). Use of TK data can provide a more robust exposure limit based on a rigorous evaluation of systemic internal dose. Bioavailability data assist in extrapolating across different routes of exposure to be protective for route-based differences of exposure. Bioaccumulation data enable extrapolation to chronic exposures when the point of departure (PoD) is from a short-term critical study. Applied in the context of chemical-specific adjustment factors (CSAFs), TK data partially replace traditional default adjustment factors for interspecies extrapolation (extrapolation from studies conducted in animals to humans) and intraspecies variability (to account for human population variability). Default adjustments of 10-fold each for interspecies and intraspecies extrapolation are recommended in several guidelines, although some organization recommend other values. Such default factors may overestimate variability for many APIs, while not being sufficiently protective for variability with other APIs. For this reason, the use of chemical specific TK and TD data are preferred. Making full use of existing TK and TD data reduces underlying uncertainties, increases transparency, and ensures that resulting ADEs reflect the best available science.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Toxicocinética , Animales , Área Bajo la Curva , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Semivida , Política de Salud , Humanos , Tasa de Depuración Metabólica , Modelos Biológicos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Especificidad de la Especie , Pruebas de ToxicidadRESUMEN
This manuscript centers on communication with key stakeholders of the concepts and program goals involved in the application of health-based pharmaceutical cleaning limits. Implementation of health-based cleaning limits, as distinct from other standards such as 1/1000th of the lowest clinical dose, is a concept recently introduced into regulatory domains. While there is a great deal of technical detail in the written framework underpinning the use of Acceptable Daily Exposures (ADEs) in cleaning (for example ISPE, 2010; Sargent et al., 2013), little is available to explain how to practically create a program which meets regulatory needs while also fulfilling good manufacturing practice (GMP) and other expectations. The lack of a harmonized approach for program implementation and communication across stakeholders can ultimately foster inappropriate application of these concepts. Thus, this period in time (2014-2017) could be considered transitional with respect to influencing best practice related to establishing health-based cleaning limits. Suggestions offered in this manuscript are intended to encourage full and accurate communication regarding both scientific and administrative elements of health-based ADE values used in pharmaceutical cleaning practice. This is a large and complex effort that requires: 1) clearly explaining key terms and definitions, 2) identification of stakeholders, 3) assessment of stakeholders' subject matter knowledge, 4) formulation of key messages fit to stakeholder needs, 5) identification of effective and timely means for communication, and 6) allocation of time, energy, and motivation for initiating and carrying through with communications.
Asunto(s)
Industria Farmacéutica , Comunicación Interdisciplinaria , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Conducta Cooperativa , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Objetivos Organizacionales , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Desarrollo de Programa , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
A European Union (EU) regulatory guideline came into effect for all new pharmaceutical products on June 1st, 2015, and for all existing pharmaceutical products on December 1st, 2015. This guideline centers around the use of the Acceptable Daily Exposure (ADE) [synonymous with the Permitted Daily Exposure (PDE)] and operational considerations associated with implementation are outlined here. The EU guidance states that all active pharmaceutical ingredients (API) require an ADE; however, other substances such as starting materials, process intermediates, and cleaning agents may benefit from an ADE. Problems in setting ADEs for these additional substances typically relate to toxicological data limitations precluding the ability to establish a formal ADE. Established methodologies such as occupational exposure limits or bands (OELs or OEBs) and the threshold of toxicological concern (TTC) can be used or adjusted for use as interim ADEs when only limited data are available and until a more formal ADE can be established. Once formal ADEs are derived, it is important that the documents are routinely updated and that these updates are communicated to appropriate stakeholders. Another key operational consideration related to data-poor substances includes the use of maximum daily dose (MDD) in setting cross-contamination limits. The MDD is an important part of the maximum allowable/safe concentration (MAC/MSC) calculation and there are important considerations for its use and definition. Finally, other considerations discussed include operational aspects of setting ADEs for pediatrics, considerations for large molecules, and risk management in shared facilities.
Asunto(s)
Industria Farmacéutica , Nivel sin Efectos Adversos Observados , Exposición Profesional/prevención & control , Salud Laboral , Preparaciones Farmacéuticas , Animales , Relación Dosis-Respuesta a Droga , Industria Farmacéutica/legislación & jurisprudencia , Industria Farmacéutica/normas , Guías como Asunto , Política de Salud , Humanos , Exposición Profesional/efectos adversos , Exposición Profesional/legislación & jurisprudencia , Exposición Profesional/normas , Salud Laboral/legislación & jurisprudencia , Salud Laboral/normas , Preparaciones Farmacéuticas/clasificación , Preparaciones Farmacéuticas/normas , Formulación de Políticas , Medición de Riesgo , Pruebas de ToxicidadRESUMEN
Occupational exposure limits (OELs) for active pharmaceutical ingredients have traditionally been established using no-observed-adverse-effect levels derived from clinical studies employing po and iv routes of administration and by applying default uncertainty factors or chemical-specific adjustment factors. However, exposure by the inhalation or dermal route is more relevant in terms of occupational safety. In this investigation, to explore new methods for route-to-route extrapolation, the bioavailability of MK-0679, a leukotriene D(4) receptor antagonist, was compared following iv, po, intranasal (in), or intratracheal (it) administration. The relative bioavailability of MK-0679 was iv congruent with it > po congruent with in. Bioavailability correction factors (BCFs) of 2.0 and 0.6 were derived from these data to adjust a hypothetical OEL of 0.1 mg/m(3) for MK-0679 with particle sizes of 10 and 50 mum, respectively. These BCFs were used to adjust the OEL established using po clinical data, to reflect the differences in bioavailability following deposition in different regions of the respiratory tract. To further investigate how bioavailability data could be used in setting OELs, a preliminary pharmacokinetic (PK) model was developed to describe the time course of plasma concentrations using the data from the route comparison study. An inhalation study was then performed to test the validity of using either empirical data or modeling approaches to derive BCFs when setting OELs. These investigations demonstrated how the use of route-specific PK data could reduce some of the uncertainties associated with route-to-route extrapolation and allow for improved precision and quantitative adjustments when establishing OELs. Further investigations are needed to better understand the factors responsible for differences in systemic uptake following deposition in different regions of the respiratory tract and how these can be generalized across different classes of soluble compounds.
Asunto(s)
Antagonistas de Leucotrieno/farmacocinética , Exposición Profesional , Preparaciones Farmacéuticas/química , Propionatos/farmacocinética , Quinolinas/farmacocinética , Animales , Disponibilidad Biológica , Antagonistas de Leucotrieno/sangre , Masculino , Propionatos/sangre , Quinolinas/sangre , Ratas , Ratas Sprague-DawleyRESUMEN
A scientific rationale is provided for estimating acceptable daily intake values (ADIs) for compounds with limited or no toxicity information to support pharmaceutical manufacturing operations. These ADIs are based on application of the "thresholds of toxicological concern" (TTC) principle, in which levels of human exposure are estimated that pose no appreciable risk to human health. The same concept has been used by the US Food and Drug Administration (FDA) to establish "thresholds of regulation" for indirect food additives and adopted by the Joint FAO/WHO Expert Committee on Food Additives for flavoring substances. In practice, these values are used as a statement of safety and indicate when no actions need to be taken in a given exposure situation. Pharmaceutical manufacturing relies on ADIs for cleaning validation of process equipment and atypical extraneous matter investigations. To provide practical guidance for handling situations where relatively unstudied compounds with limited or no toxicity data are encountered, recommendations are provided on ADI values that correspond to three categories of compounds: (1) compounds that are likely to be carcinogenic, (2) compounds that are likely to be potent or highly toxic, and (3) compounds that are not likely to be potent, highly toxic or carcinogenic. Corresponding ADIs for these categories of materials are 1, 10, and 100 microg/day, respectively.